Contrasting Enliven Therapeutics (NASDAQ:ELVN) and Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Reviva Pharmaceuticals and Enliven Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1	0	7	1	2.89
Enliven Therapeutics	1	0	5	0	2.67

Reviva Pharmaceuticals currently has a consensus target price of $3.86, indicating a potential upside of 526.06%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 88.90%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Enliven Therapeutics.

Insider and Institutional Ownership

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Reviva Pharmaceuticals and Enliven Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$29.92 million	($0.46)	-1.34
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-11.85

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reviva Pharmaceuticals and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-20,501.80%	-187.50%
Enliven Therapeutics	N/A	-24.88%	-23.96%

Risk and Volatility

Reviva Pharmaceuticals has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Summary

Reviva Pharmaceuticals beats Enliven Therapeutics on 7 of the 12 factors compared between the two stocks.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.